Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...
Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
Pharmaceutical Technology on MSN2d
Supernus’s stock sinks after depression drug fails trialThe company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...
Bonus Biogroup has received FDA approval for an IND application to conduct a Phase III clinical trial of a drug designed to treat acute respiratory distress syndrome (ARDS), especially in severe COVID ...
GlobalData on MSN9h
Boehringer and partners commence gene therapy trial for cystic fibrosisBoehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M.
Stockhead on MSN4d
Recce soars on phase II skin infection trial resultsRecce Pharmaceuticals is up ~9% today after reporting positive patient data analysis from its phase II clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback